STRM.BIO

Executive Summary

STRM.BIO is a private biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, with a focus on rare hematological diseases and in vivo CAR-T therapies. Founded in 2020 and based in San Diego, the company leverages a cell-derived delivery platform designed to overcome the limitations of traditional viral and synthetic systems. By enabling safer, targeted, and scalable genetic medicines, STRM.BIO aims to address critical unmet needs in gene therapy, particularly for patients with inherited blood disorders and cancers. The platform's ability to deliver therapeutic payloads directly to target cells in the body could significantly reduce the toxicity and complexity associated with ex vivo approaches, potentially broadening access to curative treatments. While still in early development stages, STRM.BIO's approach positions it at the forefront of next-generation gene delivery. The company's initial focus on rare hematological indications offers a clear path to clinical validation, and its expansion into in vivo CAR-T represents a high-growth opportunity in oncology. With no disclosed funding or pipeline milestones, the near-term outlook depends on advancing preclinical studies and securing partnerships. The company's success hinges on demonstrating the platform's safety and efficacy in vivo, which could unlock significant value in the rapidly evolving gene therapy landscape.

Upcoming Catalysts (preview)

• H2 2026IND submission for lead rare hematology program40% success
• Q3 2026Preclinical proof-of-concept data for in vivo CAR-T platform50% success
• Q4 2026Strategic partnership or licensing deal for delivery platform30% success